Cyprotex Launches New Predictive Modelling Solution

LONDON (Alliance News) - Cyprotex PLC Tuesday said it has launched its new predictive modelling solution, chemPK, which predicts human pharmacokinetics directly from chemical structure.

Pharmacokinetics is defined as the study of the concentration of drug in the body over time, and is based on the absorption, distribution, metabolism and excretion of a drug, Cyprotex said.

The contract research organisation said that chemPK is a virtual screening tool, meaning that it can be employed before chemical synthesis of a molecule and does not require any data inputs. The model has been optimised directly on human clinical data, therefore providing a more robust approach as compared to alternative models.

"Our new chemPK solution provides significant advantages over existing products in the market. It will provide our customers with an insight into the expected exposure of a molecule in the human body at an early stage enabling them to only synthesise compounds with the best chance of success," Chief Executive Anthony Baxter said in a statement.

Shares in Cyprotex were trading down 2.8% at 52.00 pence Tuesday morning.

By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews

Copyright 2015 Alliance News Limited. All Rights Reserved.